Vinayagamoorthy Vignesh, Srivastava Anshu, Sarma Moinak Sen
Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India.
World J Hepatol. 2021 Dec 27;13(12):2024-2038. doi: 10.4254/wjh.v13.i12.2024.
Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of disorders characterized by defects in bile secretion and presentation with intrahepatic cholestasis in infancy or childhood. The most common types include PFIC 1 (deficiency of FIC1 protein, ATP8B1 gene mutation), PFIC 2 (bile salt export pump deficiency, ABCB11 gene mutation), and PFIC 3 (multidrug resistance protein-3 deficiency, ABCB4 gene mutation). Mutational analysis of subjects with normal gamma-glutamyl transferase cholestasis of unknown etiology has led to the identification of newer variants of PFIC, known as PFIC 4, 5, and MYO5B related (sometimes known as PFIC 6). PFIC 4 is caused by the loss of function of tight junction protein 2 (TJP2) and PFIC 5 is due to NR1H4 mutation causing Farnesoid X receptor deficiency. MYO5B gene mutation causes microvillous inclusion disease (MVID) and is also associated with isolated cholestasis. Children with TJP2 related cholestasis (PFIC-4) have a variable spectrum of presentation. Some have a self-limiting disease, while others have progressive liver disease with an increased risk of hepatocellular carcinoma. Hence, frequent surveillance for hepatocellular carcinoma is recommended from infancy. PFIC-5 patients usually have rapidly progressive liver disease with early onset coagulopathy, high alpha-fetoprotein and ultimately require a liver transplant. Subjects with MYO5 B-related disease can present with isolated cholestasis or cholestasis with intractable diarrhea (MVID). These children are at risk of worsening cholestasis post intestinal transplant (IT) for MVID, hence combined intestinal and liver transplant or IT with biliary diversion is preferred. Immunohistochemistry can differentiate most of the variants of PFIC but confirmation requires genetic analysis.
进行性家族性肝内胆汁淤积症(PFIC)是一组异质性疾病,其特征为胆汁分泌缺陷,并在婴儿期或儿童期出现肝内胆汁淤积。最常见的类型包括PFIC 1(FIC1蛋白缺乏,ATP8B1基因突变)、PFIC 2(胆盐输出泵缺乏,ABCB11基因突变)和PFIC 3(多药耐药蛋白3缺乏,ABCB4基因突变)。对病因不明的γ-谷氨酰转移酶正常的胆汁淤积患者进行突变分析,已鉴定出PFIC的新变体,称为PFIC 4、5和与MYO5B相关的(有时称为PFIC 6)。PFIC 4由紧密连接蛋白2(TJP2)功能丧失引起,PFIC 5是由于NR1H4突变导致法尼醇X受体缺乏。MYO5B基因突变导致微绒毛包涵体病(MVID),也与孤立性胆汁淤积有关。患有TJP2相关胆汁淤积(PFIC-4)的儿童临床表现多样。一些患儿疾病具有自限性,而另一些则患有进行性肝病,肝细胞癌风险增加。因此,建议从婴儿期开始对肝细胞癌进行频繁监测。PFIC-5患者通常患有快速进展的肝病,早期出现凝血障碍、甲胎蛋白升高,最终需要进行肝移植。患有MYO5 B相关疾病的患者可表现为孤立性胆汁淤积或伴有顽固性腹泻的胆汁淤积(MVID)。这些儿童在因MVID进行肠道移植(IT)后有胆汁淤积恶化的风险,因此联合肠肝移植或IT并进行胆汁转流更为可取。免疫组织化学可区分大多数PFIC变体,但确诊需要基因分析。